A Risk-Benefit Assessment of Carvedilol in the Treatment of Cardiovascular Disorders
- 1 August 1994
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 11 (2) , 86-93
- https://doi.org/10.2165/00002018-199411020-00003
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- CarvedilolDrugs, 1993
- Carvedilol Inhibits Vascular Smooth Muscle Cell ProliferationJournal of Cardiovascular Pharmacology, 1993
- Safety of the Coadministration of Carvedilol and Nifedipine Sustained-Release in the Treatment of Essential HypertensionJournal of Cardiovascular Pharmacology, 1992
- Alpha Blockers and Vasodilating Beta Blockers - Influence on Factors Involved in the Pathogenesis of Vascular Disease in Patients with HypertensionClinical and Experimental Hypertension. Part A: Theory and Practice, 1989
- EFFECTS OF ANTIHYPERTENSIVE DRUGS ON CARDIOVASCULAR RISK FACTORSClinical and Experimental Pharmacology and Physiology, 1988
- Response Rate with Respect to the Blood Pressure-Lowering Effect of the Vasodilating and β-Blocking Agent CarvedilolDrugs, 1988
- The medical treatment of angina pectoris.Heart, 1987
- Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectorisThe American Journal of Cardiology, 1987
- Carvedilol for systemic hypertensionThe American Journal of Cardiology, 1987
- Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activityThe American Journal of Cardiology, 1986